| Drug Type Small molecule drug | 
| Synonyms Amlodipine besylate/olmersartan medoxomil/rosuvastatin calcium, Amlodipine/olmesartan/rosuvastatin, Olmersartan medoxomil/amlodipine besilate/rosuvastatin calcium + [5] | 
| Target | 
| Action antagonists, inhibitors, blockers | 
| Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseApproved | 
| First Approval Date South Korea (27 Feb 2019),  | 
| Regulation- | 
| Molecular FormulaC22H28CaFN3O6S | 
| InChIKeyAVDMILNVMOXCHF-DHMAKVBVSA-N | 
| CAS Registry147098-20-2 | 
| KEGG | Wiki | ATC | Drug Bank | 
|---|---|---|---|
| - | - | - | 
| Indication | Country/Location | Organization | Date | 
|---|---|---|---|
| Essential Hypertension | South Korea  | 27 Feb 2019 | |
| Primary hypercholesterolemia | South Korea  | 27 Feb 2019 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Hyperlipidemias | Phase 3 | United States  | 01 Jan 2017 | |
| Hypertension | Phase 3 | United States  | 01 Jan 2017 | 





